Since a couple of months Peter Hovstadius is the new Chief Medical Officer at XNK Therapeutics, responsible for leading the medical development of the company's products. XNK operates in biotechnology and develops cell therapies (ATMP) using natural killer cells (NK cells) for cancer treatment.
Our newsletter focuses primarily on life science and highlights key players, topics and development within the innovation ecosystem in the Stockholm-Uppsala region.
